TNF and inflammatory bowel disease: Further, the use of anti-TNF-α antibodies (adalimumab, certolizumab, infliximab, etanercept) against some inflammatory diseases (e.g., IBD, Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, spondyloarthritis) has produced contrasting results with some studies reporting increases in body mass index (BMI) and other anthropometric parameters upon treatment [16,17,18].